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Clinical ResearchLumen Gain and Restoration of Pulsatility
After Implantation of a Bioresorbable
Vascular Scaffold in Porcine Coronary ArteriesJennifer P. Lane, BS,* Laura E. L. Perkins, DVM, PHD, DACVP,* Alexander J. Sheehy, MS,*
Erica J. Pacheco, BS,y Michael P. Frie, BS,z Byron J. Lambert, PHD,*
Richard J. Rapoza, PHD,* Renu Virmani, MDy
Santa Clara, California; Gaithersburg, Maryland; and Minneapolis, MinnesotaObjectives Using intravascular ultrasound (IVUS) and histomorphometry, this study sought to
evaluate the potential of nonatherosclerotic porcine coronary arteries to undergo progressive lumen
gain and a return of pulsatility after implantation with an everolimus-eluting bioresorbable vascular
scaffold (BVS).
Background Unique beneﬁts such as lumen gain and restored vasomotion have been demonstrated
clinically after treatment with BVS; however, a more rigorous demonstration of these beneﬁts with a
randomized clinical trial has not yet been conducted.
Methods Seventy nonatherosclerotic swine received 109 everolimus-eluting BVS and 70 everolimus-
eluting metal stents randomized among the main coronary arteries. Arteries were evaluated in vivo by
angiography and IVUS and post-mortem by histomorphometry at time points from 1 to 42 months.
Results From 1 to 6 months, both BVS- and everolimus-eluting metal stent–implanted arteries
demonstrated stable lumen areas (LAs). From 12 months to 42 months, there was a progressive
increase in the LA of arteries implanted with a BVS as assessed by histomorphometry and IVUS.
This lumen gain in the implanted segment corresponded to an increase in the reference vessel
LA. Normalization in the in-segment LA (LA:reference vessel LA) was observed qualitatively by
angiography and quantitatively by IVUS. Additionally, BVS-implanted arteries demonstrated restored
in-segment pulsatility on the basis of IVUS assessment of the differences in the mid-scaffold area
between end-diastole to end-systole.
Conclusions Starting at 12 months, BVS-implanted porcine coronary arteries underwent progressive
lumen gain and showed restored pulsatility. These beneﬁts demonstrated preclinically may translate
into improvements in long-term clinical outcomes for patients treated with BVS compared with
conventional drug-eluting stents. (J Am Coll Cardiol Intv 2014;7:688–95) ª 2014 by the American
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Abbreviations
and Acronyms
BVS = bioresorbable vascular
scaffold(s)





LA = lumen area
MLD = mean lumen diameter
RLA = reference vessel lumen
area
VRT = vascular reparative
therapy
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689Drug-eluting stents (DES) currently serve as the standard of
care for the interventional treatment of occlusive coronary
artery disease; however, the success of DES has met with
challenges, including delayed healing, endothelial dysfunc-
tion, stent thrombosis, and neoatherosclerosis (1–4). These
challenges to the clinical safety and efﬁcacy of DES have
spurred the development of the latest advancement in
percutaneous coronary intervention: bioresorbable vascular
scaffolds (BVS). Beyond the approach of DES to prevent
acute recoil, subchronic remodeling, and chronic restenosis,
BVS aim to not only achieve success similar to that with
DES, but also to allow for restoration of more normal
vascular physiology, which may ultimately result in improved
late clinical outcomes (5). As BVS offer the potential for
novel therapeutic beneﬁts over conventional DES, the term
vascular reparative therapy (VRT) has been coined to
describe the novel therapy delivered by these devices.
The Absorb BVS (Abbott Vascular, Santa Clara, Cali-
fornia) is one such bioresorbable scaffold for which clinical
results to date have provided insight into the beneﬁts that
these bioresorbable devices may offer over conventional
DES. Speciﬁcally of interest are plaque regression and late
lumen gain observed serially from 6 months to 3 years in
the ABSORB family of trials (6–8). Of additional interest is
the restoration of vasomotion in the treated region
demonstrated at 12 and 36 months in Cohort B2 (8,9) and
at 24 months for cohort A of the ABSORB trial (10). These
observations provide preliminary clinical evidence that the
Absorb BVS can be distinguished frommetal platforms (bare-
metal stents, DES) that constrain coronary arteries through
permanent caging.Despite the evidence to date, we as yet await
the ﬁrst reports of long-term randomized trials comparing
these beneﬁts of Absorb BVS directly with those of DES.
In this study conducted in porcine coronary arteries, we
sought to provide insight into the clinical observations
related to the Absorb BVS. This is achieved by using his-
tological means for the direct morphometric comparison of
arteries implanted with the Absorb BVS with those im-
planted with a metal DES with the inclusion of frequent
follow-up time points. Through this comparison of the BVS
with a metal DES at multiple time points from 1 to 42
months, the performance of these devices and the chronol-
ogy at which the divergence in their performance occurs are
illustrated in vivo. In addition, we provide a novel approach
for assessing the potential beneﬁts of a BVS over a DES
through the examination of pulsatility over time.
Methods
Study devices. The Absorb BVS (Abbott Vascular) is a
balloon-expandable, fully bioresorbable scaffold that con-
sists of a poly(L-lactide) backbone with a poly(D, L-lactide)
coating in a 1:1 ratio with everolimus. The BVS investigated
in this study is the same construct as that used in Cohort Bof the ABSORB clinical trial (11). The BVS is projected to
retain radial strength through w12 months (9,12,13). The
XIENCE V Everolimus Eluting Coronary Stent System
(EES) (Abbott Vascular), which served as a metal DES
control for the study, is a balloon-expandable stent con-
sisting of a cobalt-chromium alloy that is coated with a
biocompatible ﬂuorinated copolymer. BVS and EES share
the same everolimus dose density (100 mg/cm2) and com-
parable release kinetics (14).
Animals. This study received protocol approval from the
Institutional Animal Care and Use Committee and was
conducted in accordance with American Heart Association
guidelines for preclinical research and the Guide for the Care
and Use of Laboratory Animals (15) at an Association for
Assessment and Accreditation of Laboratory Animal Care
accredited institution. Sixteen nonatherosclerotic juvenile
domestic cross-breed farm swine (ages 1 and 3 months) and
54 Yucatan mini-swine (ages 6, 12, 18, 24, 30, 36, and
42 months) were implanted via
carotid access with a BVS and an
EES. One day before the im-
plantation procedure, the pigs
received a loading dose of 325 mg
aspirin and 150 mg clopidogrel.
Thereafter, pigs were maintained
to the respective follow-up time
point on daily 81 mg aspirin
and 75 mg clopidogrel per os
through 24 months. Devices
were implanted under angio-
graphic guidance at a targeted
balloon-to-artery ratio of 1.1:1.0
(10% overstretch) according to a
predetermined randomized ma-
trix. Each animal received 1 or 2
BVS (3.0  18 mm at 1, 3, and 6 months and 3.0  12 mm
at 12, 18, 24, 30, 36, and 42 months) and 1 comparable-
length EES in the main coronary artery. Each coronary
artery was implanted with a single device as the anatomy
allowed. Devices were inﬂated at a steady rate to be
expanded to the appropriate diameter, with typical times for
complete expansion generally being 5 to 10 s for both BVS
and EES. This pressure at maximal expansion was then
maintained for up to 30 s. Devices were deployed within a
range of 5 to 20 atm. Due to the taper of the arteries, select
arteries implanted with 3.0  18-mm (1 to 6 months)
devices had a second comparable inﬂation in the proximal
region to ensure proper device apposition proximally. For
each time point, 7 to 9 animals were implanted with 12 to
13 BVS and 7 to 9 EES (Online Table 1). After device
implantation and ﬂuoroscopic assessment, animals recovered
and were maintained for the designated study period.
In vivo imaging. At the designated endpoints, pigs were
anesthetized, and implanted arteries were assessed
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690angiographically and by intravascular ultrasound (IVUS).
Angiograms (AXIOM-Artis; Siemens, Munich, Germany)
were acquired and analyzed using a PC-based quantitative
coronary angiography workstation (Siemens Leonardo,
Munich, Germany). The pre- and post-implantation mean
lumen diameters (MLDs) were measured using the internal
digital calipers of the ﬂuoroscope with the guiding catheter
serving as a reference for calibration.
IVUS (Galaxy II system or iLab Ultrasound Imaging
System, 40-Mz catheter, Boston Scientiﬁc, Natick, Mas-
sachusetts) pullbacks were acquired at an automated
pullback rate of 1.0 mm/s. Three representative still
frames from the proximal, mid, and distal regions of
the implanted segment and the proximal and distal
reference vessel within 2 mm of the implanted segment
were captured in the end-diastolic state. In addition, a
frame of the mid-implantation in the end-systolic state
was captured. The lumen area (LA) was measured in each
collected still frame. Animals were humanely euthanized
after IVUS imaging.
Histomorphometric evaluation. Hearts were excised and
pressure perfused with 0.9% saline solution followed by
pressure-perfusion ﬁxation with 10% neutral buffered
formalin overnight in preparation for histology. Formalin-
ﬁxed implanted arteries were excised from the hearts and
routinely processed for plastic embedding and embedded
in methylmethacrylate. Embedded arteries were divided
into a minimum of 3 blocks representing the proximal,
mid, and distal regions. A 4- to 6-mm section from each
of the 3 blocks was collected and stained with Movat’s
pentachrome for histomorphometric evaluation. Histo-
morphometry was performed by computerized planimetry
using IPLab version 3.9.4 r5 (Scanalytics Inc., Fairfax,
Virginia) on the 3 representative sections. The external
and internal elastic lamina areas and LA were traced.
Statistical analysis. Data are presented as mean  SD
unless otherwise noted. All statistical analysis was per-
formed with SAS.JMP version 8.0 (SAS Institute Inc.,
Cary, North Carolina). No adjustment for multiple im-
plants in an individual animal was made. For IVUS mea-
surements, a linear mixed model was used to evaluate the
time and implant effects. The overall effect of time and
treatment was evaluated using the ﬁt model platform with
standard least squares and effect leverage. In this, month of
explant is treated as a regressor and implant as a main effect
(categorical). Time and implant were crossed (time*im-
plant) for interaction effects. Normality and homogeneity
of residuals was checked with visual inspection of plotted
residuals against ﬁtted values. Because histological pro-
cessing can affect morphometric values obtained for arteries
implanted with metal and polymer devices differently,
BVS- and EES-implanted arteries were evaluated separately
for time effect by linear regression. For all tests, p < 0.05
was considered signiﬁcant.Results
All 70 animals were successfully implanted with 109
BVS and 70 EES. The baseline quantitative coronary
angiography parameters of pre-implantation MLD and post-
implantation MLD of the BVS and EES were compa-
rable and further conﬁrm successful implantation (Online
Table 2). The difference in the MLD from pre- to post-
implantation was signiﬁcantly less for the BVS- compared
with the EES-implanted arteries. This difference in acute
gain was likely related, at least in part, to the radiolucency of
polymeric BVS struts. At the scheduled follow-up, proper
device apposition to the arterial wall of both the BVS and
EES was conﬁrmed by IVUS and histology (Fig. 1).
Lumen gain. As visualized by IVUS, there was a progressive
increase in LA and scaffold area observed in BVS-implanted
arteries from 6 through 42 months (Fig. 1). Conversely, LAs
and stent areas of EES-implanted arteries remained rela-
tively stable over this same time period. Histologically, the
demonstrated luminal expansion in BVS-implanted arteries
is shown to be a benign process as arterial responses to BVS
and EES were comparable at each time point with no evi-
dence of malapposition, medial loss, or thrombosis.
Reference vessel LAs (RLAs) obtained by IVUS under-
went a progressive and coordinated expansion over time for
BVS- and EES-implanted arteries, with RLAs remaining
comparable between BVS- and EES-implanted arteries
at each time point. This increase in the RLA with time
serves as a reference to illustrate the normal growth that
porcine coronary arteries undergo (Fig. 2). Increase in the
LA of the implanted vessel segment was observed by IVUS
in BVS-implanted arteries from 12 to 42 months (Fig. 3).
Likewise, histomorphometric measures of the external and
internal elastic lamina area and LA also increased with
time in BVS-implanted arteries from 12 to 42 months
(Table 1). As demonstrated qualitatively from the IVUS still
frames in Figure 1, the progressive increase in the area
within the external elastic lamina of BVS-implanted arteries
indicates that the demonstrated quantitative lumen gain
was achieved through artery growth within the implanted
segment.
Angiographic imaging at follow-up conﬁrmed that none
of the implanted arteries showed pathological expansive
remodeling or aneurysm formation. Angiograms at later
time points illustrate longitudinal uniformity in the lumen
diameters, making the transition from the reference vessel
to the implanted segment difﬁcult to discern (Fig. 4). To
compare the time-dependent changes relative to the natural
expansion of the RLA from baseline to follow-up, normal-
ization of the in-segment LA was calculated as the ratio of
the LA to RLA (LA:RLA). For BVS-implanted arteries,
this ratio approaches 1.0 at 36 and 42 months, indicating
that the LA of the implanted segment approaches that of the
reference vessel (Fig. 5). This contrasts with the variable to
Figure 1. Representative Photomicrographs and IVUS Still Frames of BVS- and EES-Implanted Porcine Coronary Arteries Evaluated From 1 to 42 Months
Representative photomicrographs (Movat’s pentachrome, bar ¼ 500 mm) of BVS- and EES-implanted porcine coronary arteries at time points from 1 to 42 months
illustrate the benign and comparable nature of the vascular responses obtained for both devices. Corresponding IVUS still frames with matched magniﬁcation (distance
between marks ¼ 1 mm) illustrate the stable nature of the lumen artery in EES-implanted arteries and the benign increase in the lumen area and overall size of
BVS-implanted arteries appreciable from 12 to 42 months. BVS ¼ bioresorbable vascular scaffold(s); EES ¼ everolimus-eluting stent(s); IVUS ¼ intravascular ultrasound.
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Figure 3. IVUS-Obtained LA for BVS- and EES-Implanted Porcine
Coronary Arteries From 1 to 42 Months
From 1 to 12 months, EES and BVS implanted arteries follow similar trends in
LA as the arteries stabilize after implantation. From 12 to 42 months, the LA of
EES-implanted arteries remains relatively stable, whereas a progressive in-
crease in LA occurs for BVS-implanted arteries. As illustrated in Figure 2, the
lower LA at 36 months for BVS-implanted arteries is related to the smaller RLA
of these arteries at this time point. LA ¼ lumen area; other abbreviations as in
Figures 1 and 2.
Figure 2. IVUS-Obtained RLA for BVS- and EES-Implanted Porcine
Coronary Arteries From 1 to 42 Months
Both BVS- and EES-implanted arteries have progressive and corresponding
increases in RLA appreciable from 12 to 42 months. Lower RLA at 36 months
for both the BVS and EES indicates that arteries implanted at this time point
averaged smaller than those at other time points, an aspect of biological
variability that is inherent to this model. Statistical analysis illustrates the time-
dependent nature of RLA changes. RLA ¼ reference vessel lumen area; other
abbreviations as in Figure 1.
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692the decreasing ratio obtained for EES-implanted arteries
that equals 0.60 at 42 months.
Restoration of pulsatility. The IVUS LAs were captured in
the mid-implanted area of BVS- and EES-implanted ar-
teries at the same position in the end-diastolic and end-
systolic state to examine the change in pulsatility of the
implanted vessel segments over time. Results show a return
of pulsatility in BVS-implanted arteries as indicated by the
absolute difference in the lumen cross-sectional area
observed from systole to diastole (DLA). Figure 6 depicts
the average DLA over time, with notable changes beginning
at 12 months.
Discussion
In this study, we demonstrate that porcine coronary arteries
achieve signiﬁcant lumen gain and a restoration of pulsatility
after implantation with Absorb BVS as assessed by IVUS
and histomorphometry. The increase in LA of Absorb BVS-
implanted arteries coincided with an increase in artery size as
illustrated histomorphometrically by the expansion in the
area within the external elastic lamina and with IVUS
through the normalization of the LA of the implanted re-
gion with that of the reference vessel. Qualitatively, angio-
graphic comparison with EES-implanted arteries at 42
months demonstrated that the region implanted with the
BVS was difﬁcult to discern from the reference vessel as
there was no scaffold remaining and the lumen diameter ofthe implanted region effectively matched that of the refer-
ence vessel.
Along with lumen gain, the restoration of pulsatility in
Absorb BVS-implanted arteries was demonstrated with
IVUS by the progressively increasing differences between
end-diastolic and end-systolic LAs occurring in Absorb
BVS-implanted arteries from 12 to 42 months. To the best
of our knowledge, this is the ﬁrst publication in which this
technique for distinguishing a BVS from a DES in vivo has
been shown. Altogether, the lumen gain with in-segment
normalization and the restoration of pulsatility that occurred
in Absorb BVS-implanted arteries are illustrations of VRT.
This therapy has been described as being the collection of
3 phases that include ﬁrst, effective revascularization of a
narrowed artery; second, restoration of more normal vascular
function; and third, complete and benign resorption of the
scaffold (16). Results of this animal study indicate that the
second of these phases, that of restoration, becomes initially
evident around 12 months in porcine coronary arteries
implanted with the Absorb BVS.
For any BVS, the rate through which an implanted artery
travels through the 3 phases of VRT is driven by the scaf-
fold’s rate of degradation and loss of scaffolding. The pro-
gression of an artery through VRT is thus dependent on
properties inherent to the scaffold. For BVS currently being
investigated in preclinical and clinical trials, substantial
differences exist between them in their rates of degradation
and loss of scaffolding (5,17,18). For the Absorb BVS, the
Table 1. Histomorphometric Measurements of Mean EEL, IEL, and LA for BVS- and EES-Implanted Porcine Coronary Arteries
Time Point, months
EEL, mm2 IEL, mm2 LA, mm2
BVS EES BVS EES BVS EES
1 8.08  0.93 7.86  0.99 6.73  0.77 6.76  0.92 4.86  0.64 5.85  0.88
3 8.28  0.70 9.30  2.23 6.73  0.54 7.05  0.60 4.34  0.90 4.78  1.77
6 8.29  0.75 8.49  0.95 7.15  0.59 7.44  0.80 4.65  0.71 5.68  0.79
12 9.54  1.94 8.72  1.19 8.12  1.83 7.52  0.91 5.59  1.13 6.23  0.93
18 10.66  1.50 8.41  0.63 9.49  1.45 7.39  0.56 7.00  1.43 6.27  0.79
24 10.82  1.72 9.16  0.90 9.27  1.54 7.69  0.82 6.53  1.38 6.45  0.97
30 12.33  1.53 9.49  1.02 11.00  1.50 8.39  0.82 8.03  1.36 7.04  1.18
36 11.56  1.62 8.29  1.11 10.71  1.41 7.57  1.02 7.94  1.56 6.09  1.00
42 12.22  1.52 8.34  0.66 10.92  1.43 7.24  0.71 8.30  1.48 6.09  0.64
R2 0.52 <0.0001 0.58 0.056 0.55 0.09
Coefﬁcient 0.11 <0.0001 0.11 0.014 0.10 0.024
p Value <0.0001 0.99 <0.0001 0.054 <0.0001 <0.01
Values are mean  SD. Coefﬁcient of determination (R2) and p values refer to the linear regression on the basis of individual implants.
BVS ¼ bioresorbable vascular scaffold(s); EEL ¼ external elastic lamina; EES ¼ everolimus-eluting stent(s); IEL ¼ internal elastic lamina; LA ¼ lumen area.
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69312-month time point at which lumen gain and restored
pulsatility were initially observed in this study coincides with
the expected performance of the scaffold, as there is appre-
ciable loss in molecular weight and scaffold radial strength at
this time point (9,12,13).
Mechanistic insights into lumen gain. The lumen gain
observed in Absorb BVS–implanted porcine coronary ar-
teries was largely the result of expansive arterial remodeling.
In contrast, the mechanism for the lumen gain described
clinically in the ABSORB family of clinical trials has been
related instead to plaque regression (5,7). The pathophysi-
ology underlying the observed plaque regression is as yet
unknown and remains an area of research interest.
As demonstrated histologically and angiographically in
this study, the observed expansive remodeling was a benignFigure 4. Representative 42-Month Angiographic Images of BVS- and
EES-Implanted Porcine Coronary Arteries
(Left) A BVS-implanted porcine left anterior descending coronary artery with
an LA:RLA ratio of 0.98. (Right) An EES-implanted porcine right coronary ar-
tery with an LA:RLA ratio of 0.62. Arrows designate the proximal and distal
ends of the respective devices. A step change in the RLA to implanted vessel
lumen is noted in the EES-implanted arteries, whereas the lumen appears
homogeneous between the reference and implanted region in the BVS-
implanted artery. Abbreviations as in Figure 2.process not associated with aneurysmal dilation or malap-
position. Instead, this expansive remodeling was an adaptive
response driven by higher wall shear stress resulting from
both increased blood ﬂow (physiological demand) and
lumen narrowing related to neointimal proliferation in the
implanted region (19). Applying the work of Glagov et al.
(20) and others (21–23), the observation of this adaptive
remodeling in Absorb BVS–implanted arteries illustrates a
restoration of in-segment physiological ﬂuid dynamics that
occurs only subsequent to the loss of scaffolding.
Clinical correlation. A 12-month inﬂection point in lumen
gain as observed here in the preclinical setting also has been
observed clinically in the ABSORB Cohort B trial. By IVUS
and optical coherence tomography, lumen gain was reported
to occur between 6 and 36 months (6–8). Additionally, as
with the return of pulsatility demonstrated here, the return
of vasomotion in response to pharmacological agents has
been noted in the ABSORB Cohort B clinical trial begin-
ning at 12 months (8,9). Unlike other parameters related
to vascular healing that substantially differ between naive
porcine and atherosclerotic human coronary arteries (24),
this suggests that there may be a temporal correlation in
metrics related to scaffold function between the preclinical
and clinical settings.
Clinical implications. The positive morphometric changes
that occurred in Absorb BVS–implanted porcine coronary
arteries may translate clinically into decreased symptoms,
potentially improved ﬂow reserve, and an effective reduction
in or prevention of adverse events that have been related to
abnormal vascular physiology (25). Normal coronary arteries
are exposed to 2 main forces: shear stress and cyclic strain
(26,27). These forces inﬂuence the anatomy and function of
endothelial and smooth muscle cells and regulate vascular
remodeling (23,26,28,29). After metal stenting, aberrant
Figure 6. IVUS Absolute Difference Between End-Diastolic and
End-Systolic Mid-Lumen Area (DLA) in BVS- and EES-Implanted
Porcine Coronary Arteries From 1 to 42 Months
Arteries implanted with an EES demonstrate relatively stable DLA, especially
from 6 to 42 months. Over this same time period, BVS-implanted arteries
demonstrate an increase in the DLA, indicating a progressive return of
pulsatility in the implanted region. Abbreviations as in Figure 2.
Figure 5. Normalization of In-Segment LA (LA:RLA) of BVS- and
EES-Implanted Porcine Coronary Arteries as Assessed by IVUS
An LA:RLA ratio of 1.0 (gray line) indicates uniformity in the LA between the
reference vessel and the implanted region. From 1 to 6 months, EES- and BVS-
implanted arteries illustrate similar trends in the LA:RLA ratio that is related
to the peak neointimal thickness typical of this model at 3 months. For BVS-
implanted arteries, the LA:RLA ratio remains relatively stable from 6 to 30
months and increases thereafter, approaching 1.0, indicating a normalization
of the in-segment LA. Abbreviations as in Figure 2.
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694forces and a disruption of normal vascular physiology have
been demonstrated, and adverse clinical events, such as stent
thrombosis, neoatherosclerosis, and restenosis, may result
from these aberrations (2,3,19,30). Conversely, through
the interrelated events of lumen gain, normalization of
in-segment LA, and the restoration of pulsatility demon-
strated here, we show that conceptually the Absorb BVS can
allow for a return of more normalized arterial ﬂow, shear
stress, and cyclic forces.
Study limitations. The porcine coronary artery model is
the preferred model for evaluating endovascular prosthetics
due to the anatomic and physiological similarities shared
with human coronary arteries. However, although the fun-
damentals of vascular healing are the same, the non-
atherosclerotic model used here cannot completely replicate
the disease state of atherosclerotic coronary arteries. One
illustration of this in this study was the neutral edge response
observed in both EES- and BVS-implanted arteries. In
contrast, edge response has been reported with the use of
both EES and BVS (31). Although there are multiple fac-
tors contributing to the development of edge response, it is
closely related to plaque burden, which was absent in this
study (31,32). Further, as adolescent pigs were studied, as-
sessments were made in the setting of an artery that con-
tinues to demonstrate growth as opposed to the mature
or aged arteries of the clinical setting, which are limited in
their ability to undergo expansive remodeling (33). Addi-
tionally, the evaluations conducted in this study wereterminal and not serial. As arterial restoration and remod-
eling are dynamic processes, serial assessments on individual
arteries would have provided a more accurate reﬂection on
the nature and extent at which the phenomenon of lumen
gain and restored pulsatility occurred in Absorb BVS–
implanted arteries. Nevertheless, these results conducted in
normal arteries may still be indicative of changes that are
likely to occur in humans.
Conclusions
Porcine coronary arteries implanted with the Absorb BVS
demonstrate lumen gain and a restoration of pulsatility from
12 to 42 months. Although mechanisms and the presence of
disease may differ between this animal study and clinical
scenarios, the benign nature of the phenomena observed
here suggests a restoration of natural biological processes
after the loss of scaffolding. These beneﬁts demonstrated
preclinically may translate into improvements in long-term
clinical outcomes for patients treated with the Absorb BVS
compared with conventional DES.
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